Tarlatamab-Imdelltra market price, patient purchase channels and reference cost instructions

Tarlatamab (trade name: Imdelltra) is a new type of targeted antibody drug mainly used to treat specific tumor types such as small cell lung cancer. The drug specifically binds to tumor-related antigens and activates the immune system to kill tumor cells, showing good clinical efficacy. At present, talatumumab has not been officially launched in China. Patients cannot obtain it through regular hospital pharmacies, and it has not yet been included in domestic medical insurance reimbursement items.

In overseas markets, talatumumab has been approved for marketing by the US FDA in May 2024. The drug specifications include 1mg and 10mg, with prices of approximately RMB2.5 yuan and 14.8 yuan respectively. The higher price is mainly related to the fact that the drug is an original antibody drug, with high production costs and investment in innovative research and development. This also makes overseas original drugs a less affordable option for domestic patients in the short term.

There are currently no generic versions of talatumumab available, so there are no lower-cost alternatives. If patients consider using it, they need to obtain it through regular overseas medical institutions or clinical trials. They must follow the drug management regulations of the country and region where they are located to ensure that the source of the drug is legal and safe. Buying drugs on your own or obtaining them through informal channels carries greater risks.

Generally speaking, before Talatumumab is about to be launched in China, patients mainly refer to overseas prices and specifications for estimation. 1mgThe specification is about 2.5 ten thousand yuan, and the specification of 10mg is about 14.8 ten thousand yuan. There is no medical insurance coverage or generic drug options. After its domestic launch in the future, with the expansion of channels and possible inclusion in medical insurance, patient accessibility and medication costs are expected to improve. Prior to this, the use of talatumumab must strictly follow the guidance of professional doctors to ensure safety and efficacy.

Reference materials:https://www.drugs.com/